Monday, October 11, 2010

Bio Ventures for Global Health Adds Board Members

San Francisco-based BIO Ventures for Global Health (BVGH), a nonprofit focused on developing novel biotechnology-based drugs, vaccines, and diagnostics for the developing world, said it has added Burrill & Company's CEO and Founder, G. Steven Burrill, to the board, along with Genzyme's SVP, James A. Geraghty. Burrill is an active investor in biotechnology companies, and also serves on the boards of Pharmassett, Catalyst Biosciences, DepoMed, NewBridge, Proventys, Targacept, and XDx, and other organizations and companies. Geraghty is SVP at Genzyme, and is on the boards of GTC Bioteherapeutics and Bluebird Bio.